Continuing a legacy of artistic collaboration that spans centuries, Hennessy welcomes multi-disciplinary artist Ryan McGinness as the designer of the new Hennessy V.S Limited Edition bottle. McGinness’ take on the iconic Hennessy V.S label features a distinctive radiant pattern in fluorescent colors that glow under black light, and is now available for purchase online and at select wine & spirits retailers nationwide.
Known for using the visual language of contemporary symbology, the New York-based McGinness is credited with elevating the status of the icon to fine art. His works have been exhibited in museums around the world.
The new Hennessy V.S Limited Edition is the fifth in a series that has included critically acclaimed artists, KAWS, Futura, Os Gemêos and Shepard Fairey, the collaboration with McGinness is a perfect embodiment of Hennessy’s 250 years of dedication to the art of blending. McGinness acknowledges the strong similarities between his artistic approach and the creation of Hennessy Cognac: “My process of combining elements and compounds to form mixtures parallels Hennessy’s artful blending of eaux-de-vie to create Cognac. The shared approach to our crafts is part science and part art.”
To view the multimedia release please visit:
http://www.multivu.com/players/English/7582851-hennessy-ryan-mcginness-limited-edition/
http://goo.gl/OkI4zu The Final World
Order takes you to the end of the world on a whirlwind ride through the
depths of hell on earth. Can humanity save itself? Find out in the Amazon ebook on sale now at http://goo.gl/OkI4zu
SAIC, Inc. (NYSE: SAI) today held an Investor Day event in New York City in which the senior leadership team of the planned spin-off company, Science Applications International Corp. (SAIC), presented its business plans and financial objectives.
SAIC, Inc. previously announced plans to create two independent, publicly traded companies. Upon completion of the planned spin-off transaction, the technical, engineering and enterprise IT services business will retain the name SAIC and trade under (NYSE: SAIC), while the government and commercial solutions company will be named Leidos and trade under (NYSE: LDOS).
To view Multimedia News Release, go to http://www.multivu.com/mnr/63326-saic-presents-planned-company-s-business-financial-objectives-investor-day
Corporates today are on the lookout of new and novel ways to use their CSR funds effectively. A genuine step towards improving the quality of education in urban and especially rural areas would definitely interest them. And to make this possible, STEM Learning Pvt Ltd has launched Mini Science Centres (MSC) to promote experiential learning. STEM Learning is a pioneer in installing Mini Science Centres at schools in India. So far, they have installed over 40 Mega Science Centres and 250+ Mini Science Centres in Maharashtra, Gujarat, Chhattisgarh, Goa, Karnataka and Rajasthan. Their aim is to reach one million students from rural as well as urban areas of the country.
The Mini Science Project is an innovative concept developed by STEM Learning and consists of 60+ table-top models that are designed as per the syllabus of SSC, CBSC and ICSE Boards. These models come with a two-year warranty and maintenance. STEM learning also provides training to teachers to improve the effectiveness of these models in English and other vernacular languages.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7561751-stem-learning-mini-science-centre/
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program’s alignment with the United States’ Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
“We are very excited to extend our commitment to the Amgen Biotech Experience, a program that began 25 years ago, with the intent to ignite a deep passion for innovation and scientific discovery in students,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “This program, which provides advanced biotech curriculum and professional-grade lab equipment at no cost to schools, has opened countless students’ eyes to the world of biotechnology, fueling potential long term advancements to both medicine and society.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7414055-amgen-biotech-experience-grant/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
There is only one choice when it come to nutrition that slows down kidney disease and helps joint problems at the same time - The Hill's Science Diet K/D + Mobility.
Learn more here: https://tier1petproducts.com/best-dog-food-for-kidney-disease/
Chronic kidney disease (CKD) is a condition often associated with advanced age. According to recent data 1 out of 10 dogs will develop CKD in his lifetime.
It is also common for senior dogs to develop other age-related conditions such as reduced mobility or cognitive dysfunction which can significantly impact the quality of life of both the pet and the pet parent.
Nutrition can play a key role in managing these age-related conditions. That is why Hill’s nutritionists and veterinarians developed new Prescription Diet K/D + Mobility for dogs.
It’s inevitable that we’re all going to age, but Dr. Ronald Kaiser has discovered a way to make it enjoyable. In his new book Rejuvenaging: The Art and Science of Growing Older with Enthusiasm, Dr. Kaiser lays out the path to not only embracing our later years but making them the best half of our lives. Drawing on more than a half-century of clinical experience, and 80 years of living, Kaiser shares his simple plan to success. Find out more at http://www.thementalhealthgym.com/ Non-Fiction/Self Help
In Carbide Tipped Pens, over a dozen of today’s most creative imaginations explore these frontiers, carrying on the grand tradition of such legendary masters as Isaac Asimov, Robert Heinlein, and John W. Campbell, while bringing hard science fiction into the 21st century by extrapolating from the latest scientific developments and discoveries. Find out more at http://us.macmillan.com/books/9780765334305. Science fiction
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
Society for Science & the Public (Society) today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is the new title sponsor of the Science Talent Search. Selected through a competitive process that garnered interest from the nation’s leading companies and philanthropists, Regeneron will become only the third sponsor in 75 years of the nation’s oldest and most prestigious high school science competition.
The new sponsorship will be celebrated at a special event today at the American Museum of Natural History, which is known for its extensive science education program. The event will be hosted by astrophysicist Neil deGrasse Tyson, Ph.D., Frederick P. Rose director of the Hayden Planetarium at the American Museum of Natural History, and can be viewed via webcast at 9:00 a.m. EDT at http://edge.media-server.com/m/go/sciencetalentsearch.
Regeneron is committing $100 million to support the Science Talent Search and other Society programs through 2026 and will assume title sponsorship of the competition effectively immediately. As part of its commitment, Regeneron is nearly doubling the overall award distribution to $3.1 million annually, increasing the top award to $250,000, and doubling the awards for the top 300 young scientists and their schools to $2,000 each. During its history, the Science Talent Search has provided more than $25 million in awards to over 8,500 students and schools.
To view the multimedia release go to:
http://www.multivu.com/players/English/7846351-regeneron-science-talent-search/
A Princess of Roumania fantasy, with an extraordinary, intense, compressed SF novel in three parts, each set in its own alternate-history universe. The sections are all rooted in Virginia and the Battle of the Crater, and are also grounded in the real history of the Park family, from differing points of view.
The first section is set in the aftermath of the Civil War, in a world in which the Queen of the North has negotiated a two-nation settlement. The second, taking place in northwestern Massachusetts, investigates a secret project during World War II, in a time somewhat like the present. The third is set in the near-future United States, with aliens from history.
The cumulative effect is awesome. There hasn’t been a three part novel this ambitious in science fiction since Gene Wolfe’s classic The Fifth Head of Cerberus. Find out more at http://us.macmillan.com/allthosevanishedengines/PaulPark Fantasy/Scifi
